New England Journal of Medicine· 2016Q1
Palbociclib and Letrozole in Advanced Breast Cancer
- 2,971citations
- Q1SCImago
- 2016year
Short summary
Adding palbociclib to letrozole extended median progression-free survival to 24.8 months versus 14.5 months with letrozole alone in postmenopausal women with previously untreated ER-positive, HER2-negative advanced breast cancer (n=666).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine